サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1764892

アジア太平洋の緑内障治療薬市場の予測 (2031年まで) - 地域別分析 (薬剤クラス別、適応症別、流通チャネル別)

Asia Pacific Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel

出版日
ページ情報
英文 137 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.89円
アジア太平洋の緑内障治療薬市場の予測 (2031年まで) - 地域別分析 (薬剤クラス別、適応症別、流通チャネル別)
出版日: 2025年04月14日
発行: The Insight Partners
ページ情報: 英文 137 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋の緑内障治療薬市場は、2023年に12億1,180万米ドルと評価され、2031年には15億9,841万米ドルに達すると予測され、2023年から2031年までのCAGRは3.5%と推定されます。

ウェアラブル技術の開発がアジア太平洋の緑内障治療薬市場を活性化

技術革新は、正確な診断と治療改善の鍵となる最新の機器であるため、眼科を含むライフサイエンスのどの分野においても常に基本となっています。治療法の進歩により、緑内障治療の改善が可能になりました。ウェアラブル緑内障診断薬と治療薬は、潜在的な解決策として登場しました。従来の診断技術は信頼性の高い眼圧データを提供し、Sensimed Triggerfishのような革新的なコンタクトレンズは継続的な眼圧トラッキングを提供します。先進的な薬剤溶出性コンタクトレンズも、緑内障治療の潜在的ソリューションとして浮上しています。2023年3月、SpyGlass Pharma社は、初のヒト緑内障治療試験の6ヶ月データを発表しました。このデータは、薬剤溶出パッドを備えた一体型の疎水性アクリル眼内レンズである同社の新しいドラッグデリバリープラットフォームが、緑内障や高眼圧症を患う患者の眼圧を有意に低下させ続けていることを示しています。したがって、このような最新のウェアラブル製品の開発は、今後数年間、緑内障治療薬の需要を促進する可能性が高いです。

アジア太平洋の緑内障治療薬市場の概要

アジア太平洋の緑内障治療薬市場は、中国、日本、インド、オーストラリア、韓国、その他アジア太平洋に細分化されます。この地域の市場成長は、緑内障の罹患率の上昇、高齢者人口の増加、研究活動を促進するための投資の急増に起因しています。主要な市場プレーヤーは、市場でのプレゼンスを拡大するために、合併、買収、製品発売、資金調達などの戦略を採用しています。2023年2月、Zhaoke Ophthalmologyのビマトプロスト・チモロール点眼薬が緑内障治療薬として国家医療品管理局（NMPA）から販売承認を取得しました。2023年2月、参天製薬株式会社が申請していたSTN1011101点眼薬について、NMPAより販売承認を取得しました。本剤は、タフルプロスト0.0015％とチモロール0.5％を配合した防腐剤を含まない製剤で、参天製薬とAGC Inc.が共同開発しました。この治療薬は、中国における緑内障治療のアンメットニーズに応えることを目的としています。

2022年2月にBMC Ophthalmology Journalに掲載された研究によると、中国は世界で最も緑内障の罹患率が高いと報告されています。さらに、同国では2020年にすべてのタイプの緑内障患者が1,558万人に達し、その数は2050年までに2,516万人に急増すると予測されています。緑内障の高い有病率は、将来的にこの病気を管理する治療薬の成長を促進すると予想されます。中国における緑内障治療薬市場の成長は、主に各企業が採用する様々な成長戦略と高齢化人口の増加に起因しています。

アジア太平洋の緑内障治療薬市場の収益と2031年までの予測（金額）

アジア太平洋の緑内障治療薬市場のセグメンテーション

アジア太平洋の緑内障治療薬市場は、薬剤クラス別、適応症別、流通チャネル別、国別に分類されます。

薬剤クラス別では、アジア太平洋の緑内障治療薬市場は、β遮断薬、αアドレナリン作動薬、プロスタグランジン類似体、炭酸脱水酵素阻害薬、併用薬、その他に区分されます。2023年には、プロスタグランジン類縁体セグメントが最大の市場シェアを占めています。

適応症の観点から、アジア太平洋緑内障治療薬市場は開放隅角緑内障、閉塞隅角緑内障、その他に分類されます。開放隅角緑内障セグメントが2023年に最大の市場シェアを占めました。

流通チャネル別では、アジア太平洋の緑内障治療薬市場は病院薬局、小売薬局、オンライン薬局に分類されます。病院薬局セグメントが2023年に最大の市場シェアを占めました。

国別では、アジア太平洋緑内障治療薬市場は中国、日本、インド、オーストラリア、韓国、その他アジア太平洋に区分されます。2023年のアジア太平洋緑内障治療薬市場シェアは中国が独占しました。

Alcon AG、AbbVie Inc、Bausch &Lomb Inc、LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc、Santen Pharmaceutical Co,Ltd.などが、アジア太平洋の緑内障治療薬市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要洞察
  • 市場の魅力

第3章 分析手法

  • 二次調査
  • 一次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の開発
    • データの三角測量
    • 国レベルのデータ

第4章 アジア太平洋の緑内障治療薬市場：主な市場力学

  • 緑内障治療薬市場：主な市場力学
  • 市場促進要因
    • 緑内障罹患率の増加
    • 製品上市、提携、買収の増加
  • 市場抑制要因
    • 服薬コンプライアンスの問題
  • 市場機会
    • ウェアラブル技術の開発
  • 今後の動向
    • 新しい薬剤送達法の開発
  • 促進要因と抑制要因の影響

第5章 緑内障治療薬市場：アジア太平洋市場の分析

  • 緑内障治療薬市場の収益 (2021～2031年)
  • 緑内障治療薬市場の予測・分析

第6章 アジア太平洋の緑内障治療薬市場の分析：薬剤クラス別

  • β遮断薬
  • αアドレナリン作動薬
  • プロスタグランジン類縁体
  • 炭酸脱水酵素阻害薬
  • 併用薬
  • その他

第7章 アジア太平洋の緑内障治療薬市場の分析：適応症別

  • 開放隅角緑内障
  • 閉塞隅角緑内障
  • その他

第8章 アジア太平洋の緑内障治療薬市場の分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 アジア太平洋の緑内障治療薬市場：国別分析

    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋諸国

第10章 緑内障治療薬市場：業界情勢

  • 緑内障治療薬市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第11章 企業プロファイル

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第12章 付録

図表

List Of Tables

  • Table 1. Asia Pacific Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 7. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 8. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 9. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 10. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 11. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 12. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 14. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 16. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 17. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 18. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 19. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 20. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 21. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 22. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 23. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 24. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 25. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 26. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 27. Glossary of Terms

List Of Figures

  • Figure 1. Asia Pacific Glaucoma Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 4. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 5. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 12. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 16. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Asia Pacific Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 20. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 21. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Growth Strategies in Glaucoma Therapeutics Market
目次
Product Code: BMIRE00031612

The Asia Pacific glaucoma therapeutics market was valued at US$ 1,211.80 million in 2023 and is expected to reach US$ 1,598.41 million by 2031; it is estimated to register a CAGR of 3.5% from 2023 to 2031.

Development of Wearable Technologies Fuels Asia Pacific Glaucoma Therapeutics Market

Technological innovation has always been fundamental to any discipline of life sciences, including ophthalmology, as modern devices are key to accurate diagnosis and improved treatments. Advancements in treatments have enabled the improved treatment of glaucoma. Wearable glaucoma diagnostics and therapeutics products have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, while innovative contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. Advanced drug-eluting contact lenses are also emerging as a potential solution for glaucoma therapy. In March 2023, SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial. The data shows that its new drug delivery platform, which is a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to significantly lower IOP in patients suffering from glaucoma or ocular hypertension. Thus, the development of such modern wearable products is likely to propel the demand for glaucoma therapeutics in the coming years.

Asia Pacific Glaucoma Therapeutics Market Overview

The glaucoma therapeutics market in Asia Pacific is subsegmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Market growth in this region is ascribed to the rising incidence of glaucoma, the growing geriatric population, and surging investments to boost research activities. Key market players are adopting strategies such as mergers, acquisitions, product launches, and fundraising to expand their market presence. In February 2023, Zhaoke Ophthalmology's Bimatoprost Timolol eye drops received marketing authorization from the National Medical Products Administration (NMPA) for their use in glaucoma treatment. In February 2023, Santen Pharmaceutical Co., Ltd. received the marketing authorization from the NMPA for its application for STN1011101 eye drops. This preservative-free formulation containing tafluprost 0.0015% and timolol 0.5% was codeveloped by Santen and AGC Inc. The drug aims to address the unmet needs for glaucoma treatment in China.

A study published in the BMC Ophthalmology Journal in February 2022 reported that China has the highest rate of glaucoma in the world. Moreover, the country had 15.58 million people with all types of glaucoma in 2020, and the number is projected to spike up to 25.16 million by 2050. The high prevalence of glaucoma is expected to drive the growth of therapeutics to manage the disease in the future. The glaucoma therapeutics market growth in China is primarily attributed to various growth strategies adopted by market players and the increasing aging population.

Asia Pacific Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Glaucoma Therapeutics Market Segmentation

The Asia Pacific glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Asia Pacific glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Asia Pacific glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Asia Pacific glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Asia Pacific glaucoma therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Asia Pacific glaucoma therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Glaucoma Therapeutics Market - Key Market Dynamics

  • 4.1 Glaucoma Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Mounting Incidence of Glaucoma Disease
    • 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
  • 4.3 Market Restraints
    • 4.3.1 Medication Regimen Compliance Issues
  • 4.4 Market Opportunities
    • 4.4.1 Development of Wearable Technologies
  • 4.5 Future Trends
    • 4.5.1 Development of Novel Drug Delivery Methods
  • 4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - Asia Pacific Analysis

  • 5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 5.2 Glaucoma Therapeutics Market Forecast Analysis

6. Asia Pacific Glaucoma Therapeutics Market Analysis - by Drug Class

  • 6.1 Beta Blockers
    • 6.1.1 Overview
    • 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Alpha Adrenergic Agonists
    • 6.2.1 Overview
    • 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Prostaglandins Analogues
    • 6.3.1 Overview
    • 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Overview
    • 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Combination Drugs
    • 6.5.1 Overview
    • 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Glaucoma Therapeutics Market Analysis - by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Overview
    • 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Overview
    • 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Overview
    • 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Retail Pharmacy
    • 8.2.1 Overview
    • 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Online Pharmacy
    • 8.3.1 Overview
    • 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Glaucoma Therapeutics Market - Country Analysis

  • 9.1 Asia Pacific Glaucoma Therapeutics Market Overview
    • 9.1.1 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 9.1.1.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

  • 10.1 Growth Strategies in Glaucoma Therapeutics Market
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Alcon AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Bausch & Lomb Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Viatris Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Novartis AG
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Sun Pharmaceutical Industries Ltd
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Teva Pharmaceutical Industries Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Thea Pharma Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Santen Pharmaceutical Co., Ltd.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms